Table 1.
Demographic and clinical information of patients with major depressive disorders
|
Items
|
Overall MDD group (n = 206)
|
Subgroup based on follow-up data (n = 119)
|
Sig.
|
| Age (years) | 23 (10) | 22 (9) | 0.132 |
| Years of education | 14.52 ± 2.55 | 14.33 ± 2.66 | 0.530 |
| BMI (kg/m2) | 22.02 ± 4.34 | 22.43 ± 4.78 | 0.424 |
| Gender (female), No. (%) | 148 (71.8) | 87 (73.1) | 0.806 |
| Marriage (unmarried), No. (%) | 156 (75.7) | 94 (79.0) | 0.713 |
| Ethnicity (Han), No. (%) | 187 (90.8) | 109 (91.6) | 0.803 |
| History of drinking, No. (%) | 39 (18.9) | 22 (18.5) | 0.983 |
| History of smoking, No. (%) | 31 (15.0) | 17 (14.3) | 0.947 |
| Depressive episodes | 2 (1) | 2 (1) | 0.493 |
| HAMD-17 score at baseline | 21.24 ± 5.28 | 21.94 ± 5.05 | 0.557 |
| HAMD-17 score at the end of follow-up1 | NA | 10.88 ± 7.12 | < 0.001a |
| HAMA score at baseline | 21.38 ± 7.54 | 21.51 ± 7.58 | 0.883 |
| HAMA score at the end of follow-up1 | NA | 11.69 ± 7.74 | < 0.001a |
| BSSI score at baseline | 8.07 ± 7.68 | 7.57 ± 7.52 | 0.568 |
| BSSI score at the end of follow-up1 (n = 66) | NA | 5.67 ± 7.10 | 0.004a |
| SDS score at baseline | 18.50 ± 5.96 | 19.01 ± 6.07 | 0.466 |
| SDS score at the end of follow-up1 | NA | 11.91 ± 7.57 | < 0.001a |
| PDQ-5 score at baseline | 11.88 ± 3.54 | 11.69 ± 3.46 | 0.630 |
| PDQ-5 score at the end of follow-up1 | NA | 8.27 ± 4.58 | < 0.001a |
| Antidepressants at baseline | |||
| SSRIs, No. (%) | 66 (32) | 43 (36.1) | 0.451 |
| SNRIs, No. (%) | 20 (9.7) | 12 (10.1) | 0.913 |
| SARIs, No. (%) | 98 (47.6) | 62 (52.1) | 0.432 |
| Others2, No. (%) | 14 (6.8) | 7 (5.9) | 0.747 |
| Antidepressants at the end of follow-up | |||
| SSRIs, No. (%) | NA | 67 (32.5) | NA |
| SNRIs, No. (%) | NA | 18 (8.7) | NA |
| SARIs, No. (%) | NA | 86 (41.7) | NA |
| Others2, No. (%) | NA | 21 (17.6) | NA |
| Neuroticism score at baseline | 44.92 ± 5.97 | 45.05 ± 5.70 | 0.919 |
| T-AI score at baseline | 59.98 ± 7.06 | 60.15 ± 6.80 | 0.824 |
| PSS score at baseline | 24.76 ± 4.96 | 24.83 ± 5.28 | 0.899 |
| S-AI score at baseline | 56.64 ± 8.67 | 56.47 ± 8.06 | 0.858 |
P < 0.05.
Comparison of clinical manifestations between baseline and the end of the 8-week follow-up.
Others include Noradrenergic and Specific Serotonergic Antidepressants and Norepinephrine-Dopamine Reuptake Inhibitors.
BMI: Body mass index; HAMD-17: 17-item Hamilton Depression Scale; HAMA: Hamilton Anxiety Scale; BSSI: Beck Scale for Suicide Ideation; SDS: Sheehan Disability Scale; PDQ-5: Perceived Deficits Questionnaire five-item version; SSRIs: Selective Serotonin Reuptake Inhibitors; SNRIs: Serotonin-Norepinephrine Reuptake Inhibitors; SARIs: Serotonin Receptor Antagonists and Reuptake Inhibitors; T-AI: Trait Anxiety Inventory of State-Trait Anxiety Inventory; PSS: Perceived Stress Scale; S-AI: State Anxiety Inventory of State-Trait Anxiety Inventory; NA: Not available.